Stent implantation in acute myocardial infarction

Garcia-Cantu, Elias; Spaulding, Christian; Corcos, Thierry; Hamda, Khaldoun Ben; Roussel, Laurent; Favereau, Xavier; Guérin, Yves; Chalet, Y.; Souffrant, G; Guérin, François

doi:10.1016/s0002-9149(97)89336-8

Cited by 67 publications

(13 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…12 Procedural secondary end points included device success (attainment of Ͻ50% in-stent residual stenosis of the target lesion, as measured by QCA, using the assigned device), lesion success (attainment of Ͻ50% residual stenosis of the target lesion, as measured by QCA, using any percutaneous method), and procedure success (attainment of a final lesion success and no in-hospital major adverse cardiac events), as previously described. 13 Secondary angiographic end points included in-stent and insegment binary restenosis and in-stent minimal lumen diameter (MLD). The IVUS end point was percent neointimal volume obstruction, (neointimal volume/stent volumeϫ100).…”

Section: Outcomes and Data Managementmentioning

confidence: 99%

Six-Month Results of the NEVO RES-ELUTION I (NEVO RES-I) Trial

Ormiston

Abizaid

Spertus

et al. 2010

Circ: Cardiovascular Interventions

Self Cite

View full text Add to dashboard Cite

on behalf of the NEVO ResElution-I InvestigatorsBackground-Drug-eluting stents reduce restenosis and reintervention rates but are complicated by stent thrombosis, which may be related to polymer coating. The NEVO sirolimus-eluting coronary stent (NEVO SES) is designed to improve long-term percutaneous coronary intervention safety by combining sirolimus release from reservoirs with bioabsorbable polymer to reduce spatial and temporal polymer exposure. Methods and Results-NEVO ResElution-I was a prospective randomized study in 394 patients with coronary artery disease comparing the NEVO SES with the TAXUS Liberté paclitaxel-eluting coronary stent (TAXUS Liberté PES) stent. The primary end point was in-stent angiographic late loss at 6 months. Six months after percutaneous coronary intervention (PCI), the primary end point favored NEVO SES (0.13Ϯ0.31 mm versus 0.36Ϯ0.48 mm, PϽ0.001 for noninferiority and superiority). The study was not powered for clinical end points and showed no significant difference for NEVO SES versus TAXUS Liberté PES: death: 0.5 versus 1.6%, Pϭ0.36; myocardial infarction: 2.0 versus 2.6%, Pϭ0.75; target lesion revascularization: 1.5 versus 3.2%, Pϭ0.33; major adverse cardiac events: 4.0 versus 7. 4%, Pϭ0.19. No stent thrombosis was observed with NEVO SES, whereas 2 cases occurred in TAXUS Liberté PES. Intravascular ultrasound showed lower percent volume obstruction for NEVO SES (5.5Ϯ11% versus 11.5Ϯ9.7%, Pϭ0.016). Key Words: angioplasty Ⅲ stents Ⅲ restenosis S ince the introduction of the CYPHER sirolimus-eluting coronary stent (CYPHER SES) in 2002, many trials have established that release of sirolimus from a nonerodible polymer significantly reduces restenosis and repeat intervention rates compared with bare-metal and other drug-eluting stents (DES) in a wide variety of clinical settings. [1][2][3][4][5] However, the clinical benefit of DES may be partially offset by a heightened incidence of late stent thrombosis. 6,7 Although the causes of late stent thrombosis are multifactorial, permanent polymer surface coatings may play a key role by inciting an inflammatory response because of permanent exposure of the polymer to the vessel wall, even long after the drug has been completely released. 8 Eliminating this risk requires DES developments that reduce both polymer exposure over time Received February 13, 2010; accepted August 23, 2010 Clinical Perspective on p 564 Conclusions-ThisThe NEVO sirolimus-eluting coronary stent (NEVO SES) (Cordis Corporation, Bridgewater, NJ) is a new cobaltchromium alloy stent platform that incorporates unique reservoir technology and a bioabsorbable polymer from which sirolimus is released. These design elements, accomplished by creating multiple laser-cut reservoirs and then filling them with a blend of sirolimus and the bioabsorbable polymer, reduce the amount of tissue exposed to the polymer. Absorption of the polymer within approximately 3 months limits the duration of vessel wall exposure to the polymer. Thereafter, only a biologically inert bare-metal pla...

show abstract

Section: Outcomes and Data Managementmentioning

confidence: 99%

Six-Month Results of the NEVO RES-ELUTION I (NEVO RES-I) Trial

Ormiston

Abizaid

Spertus

et al. 2010

Circ: Cardiovascular Interventions

Self Cite

View full text Add to dashboard Cite

show abstract

“…The best results for clopidogrel were observed in the PAOD Recently, many cardiologists are advocating the combined use of aspirin and ticlopidine in patients receiving Palmaz-Schatz stents. Recent reports by cardiologists (71)(72)(73) have led to a wide acceptance of the combination of ASA and ticlopidine in patients receiving coronary stents. These studies indicated that the combined use of ticlopidine and aspirin after stenting reduced the bleeding incidence compared with the vitamin K antagonists.…”

Section: Results Of the Caprie Studymentioning

confidence: 99%

Antiplatelet Agents in Cardiovascular and Cerebrovascular Diseases

Breddin¹

1998

Clin Appl Thromb Hemost

View full text Add to dashboard Cite

Aspirin has become a widely accepted platelet function inhibitor and is used to prevent arterial occlusions in coronary cerebral and peripheral vascular disease. The results of clinical studies with aspirin in the area of peripheral arterial occlusive disease are critically reviewed. Two thienopyridine compounds, ticlopidine and clopidogrel, have been effectively used in the prevention of myocardial infarction and stroke in several clinical trials, especially in the recently published CAPRIE-trial. Potent new platelet function inhibitors recently were developed. Intravenous treatment with abciximab, a new platelet membrane glycoprotein IIb/IIIa-inhibitor, effectively prevented coronary reocclusions in patients with high-risk coronary events. A series of promising new oral IIb/IIIainhibitors have been developed and may become effective drugs in the prevention of reocclusions in patients with peripheral vascular disease and in coronary or cerebral vascular disease.

show abstract

“…However, with improvements in the stent deployment technique and the availability of more effective antithrombotic therapy, several trials of stenting for AMI have reported its feasibility and efficacy. [3][4][5][6][7][8][9][10] The new antithrombotic therapy of combining aspirin and ticlopidine was reported by Colombo et al 11 to reduce stent thrombosis event rates as low as 0.6% (acute stent thrombosis) and 0.3% (subacute stent thrombosis).…”

Section: Discussionmentioning

confidence: 99%

“…ecause intracoronary stenting effectively reduces the acute complications and restenosis rates of conventional percutaneous transluminal coronary angioplasty, 1,2 the use of stents has been extended to thrombotic as well as non-thrombotic lesions [3][4][5][6][7][8][9][10] by optimizing the stent dilatation under intravascular ultrasound (IVUS) guidance and supplemental oral administration of ticlopidine, both of which are effective in reducing stent thrombosis. 11 …”

mentioning

confidence: 99%

Usefulness of Intracoronary Angioscopy for Elucidating the Cause of Subacute Thrombosis After Stenting

et al. 2001

View full text Add to dashboard Cite

Stent thrombosis is rare with anti-platelet therapy, which consists of aspirin and ticlopidine as a post-stenting administration. A 77-year-old man had repeated stent thrombosis, which was not predicted by coronary angiography, despite using contemporary periprocedural anti-platelet therapy. Only intravascular fiberscopy was able to detect the cause of the stent thrombosis. (Jpn Circ J 2001; 65: 232 -235)

show abstract

Stent implantation in acute myocardial infarction

Cited by 67 publications

References 18 publications

Six-Month Results of the NEVO RES-ELUTION I (NEVO RES-I) Trial

Six-Month Results of the NEVO RES-ELUTION I (NEVO RES-I) Trial

Antiplatelet Agents in Cardiovascular and Cerebrovascular Diseases

Usefulness of Intracoronary Angioscopy for Elucidating the Cause of Subacute Thrombosis After Stenting

Contact Info

Product

Resources

About